- Home
- FINV vs SGP Comparison
FINV vs SGP Comparison
Compare FINV & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FINV | SGP |
|---|---|---|
| Founded | 2007 | 2019 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 739.0M | 799.4M |
| IPO Year | 2017 | 2026 |
Fundamental Metrics
Financial Performance| Metric | FINV | SGP |
|---|---|---|
| Price | $3.13 | $24.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $5.58 | ★ $44.00 |
| AVG Volume (30 Days) | ★ 836.9K | 109.2K |
| Earning Date | 11-18-2026 | 11-10-2026 |
| Dividend Yield | ★ 9.68% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.87 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.89 | $17.06 |
| 52 Week High | $7.07 | $32.44 |
Technical Indicators
Market Signals| Indicator | FINV | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 45.05 | 42.91 |
| Support Level | $2.89 | $20.95 |
| Resistance Level | $3.25 | $25.83 |
| Average True Range (ATR) | 0.10 | 1.37 |
| MACD | 0.05 | -0.16 |
| Stochastic Oscillator | 63.89 | 38.82 |
Price Performance
Historical ComparisonAbout FINV FinVolution Group
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.
About SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.